TXG · 10x Genomics, Inc. · Webcasts, Transcripts & Audio
$58.19
-0.91 (-1.54%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$7.65B
Shares
131.53M
Volume · Nov 13
2.13M
Avg daily vol (3M)
3.35M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
10x Genomics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for 10x Genomics, Inc. (TXG), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-17
10x Genomics, Inc. (TXG) November 17, 2026 Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-05
10x Genomics, Inc. (TXG) Q3 2026 Earnings Call Transcript
Positive tone
AI-driven biological data demand
Single-cell FlexApex adoption
Atera commercial launch and demand
Revenue
$150.67M
▲ 1.1% YoY Diluted EPS
$-0.15
Gross margin
75.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-08-06
10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcript
Confident tone
Atera launch and customer demand
Xenium and Visium spatial momentum
Q3-to-Q4 sequential step-up and guidance
Revenue
$151.04M
▼ 12.6% YoY Diluted EPS
$-0.14
▼ 150% YoY Gross margin
74.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-13
10x Genomics, Inc. (TXG) May 13, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
10x Genomics, Inc. (TXG) Q1 2026 Earnings Call Transcript
Confident tone
Atara launch
Single cell / FLEX growth
Spatial / Xenium momentum
Revenue
$150.84M
▼ 2.6% YoY Diluted EPS
$-0.10
Gross margin
70.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-12
10x Genomics, Inc. (TXG) Q4 2025 Earnings Call Transcript
Positive tone
Spatial / Xenium momentum
Revenue and demand environment
Single cell consumables and FLEX APEX
Revenue
$166.03M*
▲ 0.6% YoY Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Conference
Investor event
2026-01-12
10x Genomics, Inc. (TXG) January 12, 2026 Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-06
10x Genomics, Inc. (TXG) Q3 2025 Earnings Call Transcript
Positive tone
Single-cell / Chromium strategy
Macro and funding environment
Xenium and spatial growth
Revenue
$149.00M
▼ 1.7% YoY Diluted EPS
$-0.22
Gross margin
67.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
10x Genomics, Inc. (TXG) Q2 2025 Earnings Call Transcript
Balanced tone
Bruker Litigation Settlement
China Tariff Dynamics
Spatial / Xenium Growth
Revenue
$172.91M
▲ 12.9% YoY Diluted EPS
$0.28
Gross margin
72.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Annual General Meeting
Investor event
2025-06-03
10x Genomics, Inc. (TXG) June 3, 2025 Annual General Meeting Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q1
2025-05-08
10x Genomics, Inc. (TXG) Q1 2025 Earnings Call Transcript
Cautious tone
Single Cell and Spatial Adoption
Macro/NIH Funding Environment
Workforce Reduction and Cost Actions
Revenue
$154.88M
▲ 9.8% YoY Diluted EPS
$-0.28
Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-12
10x Genomics, Inc. (TXG) Q4 2024 Earnings Call Transcript
Positive tone
2025 guidance and outlook
2024 financial results
Spatial business growth
Revenue
$165.02M*
▼ 10.3% YoY Gross margin
67.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-29
10x Genomics, Inc. (TXG) Q3 2024 Earnings Call Transcript
Cautious tone
Revenue shortfall and guidance
Chromium pricing and accessibility
Commercial restructuring disruption
Revenue
$151.65M
▼ 1.3% YoY Diluted EPS
$-0.30
Gross margin
70.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
10x Genomics, Inc. (TXG) Q2 2024 Earnings Call Transcript
Cautious tone
Visium and CytAssist strength
Xenium platform and instrument sales
Single cell / Chromium momentum
Revenue
$153.10M
▲ 4.3% YoY Diluted EPS
$-0.32
Gross margin
68.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-30
10x Genomics, Inc. (TXG) Q1 2024 Earnings Call Transcript
Positive tone
Chromium transition headwinds
Platform investment balance
Spatial biology momentum
Revenue
$141.01M
▲ 5% YoY Diluted EPS
$-0.50
Gross margin
65.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
10x Genomics, Inc. (TXG) Q4 2023 Earnings Call Transcript
Positive tone
Xenium platform launch and adoption
GEM-X Chromium overhaul
Visium HD upcoming launch
Revenue
$183.98M*
▲ 17.8% YoY Gross margin
62.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
10x Genomics, Inc. (TXG) Q3 2023 Earnings Call Transcript
Revenue
$153.64M
▲ 17.2% YoY Diluted EPS
$-0.79
Gross margin
62.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
10x Genomics, Inc. (TXG) Q2 2023 Earnings Call Transcript
Revenue
$146.82M
▲ 28.1% YoY Diluted EPS
$-0.53
Gross margin
67.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-03
10x Genomics, Inc. (TXG) Q1 2023 Earnings Call Transcript
Revenue
$134.28M
▲ 17.3% YoY Diluted EPS
$-0.44
Gross margin
73.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-15
10x Genomics, Inc. (TXG) Q4 2022 Earnings Call Transcript
Revenue
$156.23M*
▲ 8.8% YoY Gross margin
76.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-02
10x Genomics, Inc. (TXG) Q3 2022 Earnings Call Transcript
Revenue
$131.07M
▲ 4.6% YoY Diluted EPS
$-0.37
Gross margin
76.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
10x Genomics, Inc. (TXG) Q2 2022 Earnings Call Transcript
Revenue
$114.61M
▼ 1.1% YoY Diluted EPS
$-0.57
Gross margin
75.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
10x Genomics, Inc. (TXG) Q1 2022 Earnings Call Transcript
Revenue
$114.50M
▲ 8.2% YoY Diluted EPS
$-0.38
Gross margin
77.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-16
10x Genomics, Inc. (TXG) Q4 2021 Earnings Call Transcript
Revenue
$143.53M*
▲ 27.9% YoY Gross margin
80.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
10x Genomics, Inc. (TXG) Q3 2021 Earnings Call Transcript
Revenue
$125.30M
▲ 74.5% YoY Diluted EPS
$-0.15
Gross margin
80.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
10x Genomics, Inc. (TXG) Q2 2021 Earnings Call Transcript
Revenue
$115.84M
▲ 170% YoY Diluted EPS
$-0.10
Gross margin
95.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
10x Genomics, Inc. (TXG) Q1 2021 Earnings Call Transcript
Revenue
$105.82M
▲ 47.2% YoY Diluted EPS
$-0.11
Gross margin
83.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
10x Genomics, Inc. (TXG) Q4 2020 Earnings Call Transcript
Revenue
$112.22M*
▲ 49% YoY Gross margin
83.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
10x Genomics, Inc. (TXG) Q3 2020 Earnings Call Transcript
Revenue
$71.82M
▲ 17.3% YoY Diluted EPS
$-0.65
Gross margin
79.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-11
10x Genomics, Inc. (TXG) Q2 2020 Earnings Call Transcript
Revenue
$42.91M
▼ 23.1% YoY Diluted EPS
$-0.41
Gross margin
76.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
10x Genomics, Inc. (TXG) Q1 2020 Earnings Call Transcript
Revenue
$71.91M
▲ 34.2% YoY Diluted EPS
$-0.22
Gross margin
79.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-18
10x Genomics, Inc. (TXG) Q4 2019 Earnings Call
Revenue
$75.29M
▲ 48.9% YoY Gross margin
78.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 webcasts
Key facts
CIK
1770787
CUSIP
88025U109
13F (30d)
389 filings
351 filers
Visit website
Investor relations